Premarket Movers Nov 20, 2026: Why VWAV, AKAN, RAYA Are Up
Premarket movers today: VisionWave, Akanda, Erayak, DataMeds AI and Capricor are surging before the open. Here is why each is up and what the risks are.
VWAV — VisionWave Holdings, Inc. (+50.3%)
VisionWave is up 50.3% in premarket trading to $0.99, vs the prior close. About 38.5 million shares have changed hands, far above its 20-day average of roughly 3.4 million. The market cap is only about $19.1 million, so this is a very small company.
The likely catalyst is VisionWave's November 20 announcement that it acquired the Critical Minerals Intelligence Platform (CMIP) from Litial Ltd. The company's press release, filed with the SEC, describes CMIP as a platform for market intelligence, supply-chain transparency and regulatory screening for critical minerals. GuruFocus reports the shares rose about 24% in early trading after the news and says the deal was signed November 18. The roughly 50% move above is the premarket figure; the outside reports cite a smaller gain.
There is recent history here. On November 18, Benzinga reported VWAV closed up 57.07% at $0.78, then fell about 18.74% after hours following three international defense-related commercial arrangements that came with no customer orders. This stock swings hard in both directions.
The prior-day setup is weak. The daily chart carried no active pattern signal, with RSI at 26, a bearish moving-average stack and the stock about 99.8% below its 52-week high. Conviction is 40/100 (grade D). Free float is 36.9% (the share of stock actually available to trade), short-volume is 47%, and a short-sale restriction is active. Treat this as a news-driven spike in a deeply beaten-down name.
AKAN — AKANDA CORP. (+48.1%)
Akanda is up 48.1% premarket to $5.16 on about 12.4 million shares, a bit under its 20-day average of 16.5 million. Market cap is about $9.9 million. The stock has been a regular on our recaps, including Top Stock Movers Nov 18.
No news, filing or announcement explains today's move. The most recent headlines are about volatility: a 62% jump on November 17, a 13.9% slide on November 19 after a triple-digit rally, and a roughly 10% premarket drop that same morning. This looks momentum-driven rather than news-driven. The only recent filing is an F-1/A from November 6, a registration-related filing.
On the prior-day chart there was no active pattern signal. RSI was 71, ADX 37, the moving-average stack was mixed, and the stock sat about 95.6% below its 52-wk high. Conviction is 4/100 (grade D), though relative strength is 99. Free float is 90.7%, short-volume is 44% and a short-sale restriction is active. Reddit chatter on r/pennystocks is light (rank #105).
RAYA — Erayak Power Solution Group Inc. (+46.9%)
Erayak is up 46.9% premarket to $0.72 on about 39.2 million shares, versus a 20-day average of 5.8 million. Market cap is about $5.4 million. A Moomoo headline put the premarket gain even higher, at 84.15%, so the price has been swinging widely.
No news, filing or announcement explains the move. The only recent filing is a passive Schedule 13G from November 17, which is a routine stake disclosure, not a catalyst. With nothing to point to, this looks momentum-driven.
The prior-day setup was weak: no pattern signal, RSI 26, a bearish moving-average stack, and a price about 99% below its 52-week high. Conviction is 36/100 (grade D). Free float is 99.6%, so this is not a low-float squeeze story. Short-volume was 63%. Smart-money score is 17/100, with a largest disclosed stake of 5.0%.
MEDS — DataMeds AI, Inc. (+31.5%)
DataMeds AI is up 31.5% premarket to $0.95 on about 11.6 million shares, against a 20-day average of about 872,000. That is heavy volume relative to normal. Market cap is about $4.1 million. We covered the after-hours jump in After-Hours Movers Nov 19.
The likely catalyst: after the November 19 close, DataMeds said it agreed to acquire select assets from the estate of Israeli diagnostics company Todos Medical. They include the TBIA breast and colorectal cancer blood-test platform and Todos' license to the LymPro Alzheimer's blood test. The deal needs court approval. The company plans to validate TBIA before pursuing a lab-developed-test launch and an FDA pathway. Benzinga reported the stock rose 55.28% to $1.13 after hours from a $0.73 close, so the premarket gain is smaller than the after-hours spike.
Dilution is a risk. The company disclosed an at-the-market stock sales agreement in mid-November with no stated maximum, and filed two 424B5 prospectus supplements on November 16 and 17. That means it can sell new shares into strength, which can cap rallies. This was background, not the stated reason for the move.
On the prior-day chart, an inverted hammer candle appeared, with RSI at 28 and the stock about 94.1% below its 52-week high. Conviction is 40/100 (grade D). Free float is 100%, short-volume 50%, and smart-money score 17/100.
CAPR — CAPRICOR THERAPEUTICS, INC. (+17.3%)
Capricor is up 17.3% premarket to $8.83, but on only about 710,000 shares versus a 20-day average of 4.7 million. Premarket volume is light, so the move is less established. It is the largest company here, with a market cap of about $437.8 million.
No news, filing or announcement dated November 19–20 clearly explains the move. Recent headlines center on the FDA decision on its Duchenne therapy, deramiocel. A TradingView headline from November 19 says the FDA extended the review, and the company reported a Q3 loss. Whether that relates to today's gain is unclear, so treat the cause as unconfirmed. The company also reported a positive Phase 3 trial result earlier in 2026, which is background.
The prior-day chart showed a three black crows candle, a bearish pattern of three long down days. RSI was 46, the moving-average stack bearish, and the stock about 81.3% below its 52-week high, though relative strength is 99. Conviction is 18/100 (grade D). Free float is 71.7%, short-volume 59%, and smart-money score 28/100 with a largest disclosed stake of 5.1%. Regulatory news can move biotech stocks sharply in either direction.
The bottom line
Every name here is a volatile, mostly sub-$20 million company, and premarket prices are thin and can reverse fast once the 9:30 AM ET open arrives. Big gainers often give back much of the move. Patterns and squeezes fail, dilution can cap rallies, and nothing here is a recommendation. Manage your risk and do your own research.
StockSetups scans the full US universe after every close and every premarket morning, detecting chart patterns and scoring conviction, squeeze potential and trend strength so you can see the setup behind each move. For more on how we use trend context, see Price Action Trading: Reading Charts Without Indicators. This article is educational only.
Frequently asked questions
Why is VWAV up today?
VisionWave announced on November 20, 2026 that it acquired the Critical Minerals Intelligence Platform (CMIP) from Litial Ltd. The stock is up about 50% premarket, but it is a tiny, volatile company and has swung sharply in recent days.
Why is MEDS up premarket?
DataMeds AI agreed after the November 19 close to acquire select assets from the Todos Medical estate, including the TBIA cancer blood-test platform. The deal needs court approval, and the company also has an at-the-market stock sales agreement that could dilute shareholders.
What is a low-float short squeeze?
Float is the number of shares available to trade. When it is small and many traders are short, buying can force shorts to cover, pushing the price up quickly. Squeezes often reverse just as fast.
Are premarket movers safe to chase?
No. Premarket volume is light, spreads are wide and prices can reverse at the open. Large one-day gainers frequently give back much of the move.
Produced with AI assistance and published under the StockSetups editorial guidelines.
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy